Odyssey Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 19.54 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 936.33M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Details
| Name | Odyssey Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 100 |
| Founded | 2021 |
| Ipo Date | 2026-05-08 |
| Ceo | Gary Glick |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 18.00 |
| Isin | US67613T1043 |
| Cusip | 67613T104 |
| Cik | 1882782 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Gary D. Glick Ph.D. | Founder, President, Chief Executive Officer and Director |
| Jason Haas M.B.A. | Chief Financial Officer |
| Collin Todd | Senior Vice President of Strategy and Business Development |
| Prof. Eicke Latz M.D., Ph.D. | Scientific Co-Founder |
| Dr. Kim Lewis Ph.D. | Scientific Co-Founder |
| Dr. Felix Meissner Ph.D. | Scientific Co-Founder |
| Dr. Florian.I Schmidt Ph.D. | Scientific Co-Founder |
| Jolie M. Siegel J.D. | Executive Vice President, General Counsel and Secretary |
| Dr. Natalie Dales Ph.D. | Chief of Research Operations and Portfolio Strategy |
| Dr. Joseph McDonald Ph.D. | Chief Data Officer |
Contact
| Address | 51 Sleeper Street, Suite 800, Boston, Massachusetts 02210, United States |
| Phone | 617 865 9628 |
| Website | https://odysseytx.com |